Compare Levi Strauss & Co. (LEVI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Novo Nordisk A/S — how do they compare? Levi Strauss & Co. trades at $22.57 (market cap $8.75B), while Novo Nordisk A/S trades at $46.23 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 23.8× Levi Strauss & Co.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| LEVI | NVO | |
|---|---|---|
Market Cap | $8.75B | $207.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $63.98 |
52-Week Low | $17.92 | $35.29 |
Enterprise Value | $10.07B | $222.55B |
Dividend Yield | 2.81% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss & Co. (LEVI) trades at $23.59, down 3.32% over 24 hours, amid a recent cybersecurity incident disclosed on August 7, 2026. The stock shows strong fundamentals with a P/E of 16.24, robust gross margin of 61.72%, and consistent earnings beats in recent quarters. Technical indicators are bearish, with support near $23, while analyst consensus remains bullish with a $27.88 price target.
The outlook for LEVI is positive due to solid DTC growth and raised 2026 guidance, but risks include cybersecurity concerns and tariff pressures. Earnings momentum and a reasonable valuation support upside potential, though near-term volatility may persist from the security breach and market reactions.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
